FIDELIO-DKD (2020) — Trial Summary
FIDELIO-DKD (2020): Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduced risk of kidney failure and cardiovascular events in patients with type 2 diabetes and CKD.
References
- Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229.